دورية أكاديمية
أعرض في EDS

Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.

التفاصيل البيبلوغرافية
العنوان: Enhancing cancer immunotherapy via inhibition of soluble epoxide hydrolase.
المؤلفون: Kelly AG; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Wang W; Department of Entomology and Nematology, University of California, Davis, CA 95616.; University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817.; Department of Food Science, Purdue University, West Lafayette, IN 47907., Rothenberger E; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Yang J; Department of Entomology and Nematology, University of California, Davis, CA 95616.; University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817., Gilligan MM; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Kipper FC; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Attaya A; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Gartung A; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Hwang SH; Department of Entomology and Nematology, University of California, Davis, CA 95616.; University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817., Gillespie MJ; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Bayer RL; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Quinlivan KM; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Torres KL; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215., Huang S; Institute of Systems Biology, Seattle, WA 98109., Mitsiades N; University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817.; Department of Internal Medicine, University of California Davis, CA 95817., Yang H; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Food Nutrition and Safety, College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China., Hammock BD; Department of Entomology and Nematology, University of California, Davis, CA 95616.; University of California Davis Comprehensive Cancer Center, Sacramento, CA 95817., Panigrahy D; Center for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.; Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
المصدر: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2024 Feb 13; Vol. 121 (7), pp. e2314085121. Date of Electronic Publication: 2024 Feb 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: National Academy of Sciences Country of Publication: United States NLM ID: 7505876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1091-6490 (Electronic) Linking ISSN: 00278424 NLM ISO Abbreviation: Proc Natl Acad Sci U S A Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : National Academy of Sciences
مواضيع طبية MeSH: Epoxide Hydrolases*/metabolism , Neoplasms*/therapy, Mice ; Humans ; Animals ; Fatty Acids/metabolism ; Inflammation/metabolism ; Immunotherapy ; Tumor Microenvironment
مستخلص: Cancer therapy, including immunotherapy, is inherently limited by chronic inflammation-induced tumorigenesis and toxicity within the tumor microenvironment. Thus, stimulating the resolution of inflammation may enhance immunotherapy and improve the toxicity of immune checkpoint inhibition (ICI). As epoxy-fatty acids (EpFAs) are degraded by the enzyme soluble epoxide hydrolase (sEH), the inhibition of sEH increases endogenous EpFA levels to promote the resolution of cancer-associated inflammation. Here, we demonstrate that systemic treatment with ICI induces sEH expression in multiple murine cancer models. Dietary omega-3 polyunsaturated fatty acid supplementation and pharmacologic sEH inhibition, both alone and in combination, significantly enhance anti-tumor activity of ICI in these models. Notably, pharmacological abrogation of the sEH pathway alone or in combination with ICI counter-regulates an ICI-induced pro-inflammatory and pro-tumorigenic cytokine storm. Thus, modulating endogenous EpFA levels through dietary supplementation or sEH inhibition may represent a unique strategy to enhance the anti-tumor activity of paradigm cancer therapies.
Competing Interests: Competing interests statement:J.Y., S.H.H., and B.D.H. are affiliated with EicOsis Human Health which has a sEH inhibitor in human 1b safety trials. J.Y., S.H.H., and B.D.H. have stock options in EicOsis Human Health to disclose. The authors disclose the following patent filing: E.R., S.H.H., B.D.H., and D.P. Methods of Improving Cancer Immunotherapy. Provisional Application No. 63/326,504 filed April 1, 2022. Use of dual COX-2/sEH inhibitors with immunotherapy Use of dual COX-2/sEH inhibitors with immunotherapy. D.P. has received consulting fees from attorneys representing plaintiffs in cases involving exposure to chemical agents. The other authors declare they have no actual or potential competing financial interests.
التعليقات: Comment in: Proc Natl Acad Sci U S A. 2024 Feb 27;121(9):e2400431121. (PMID: 38354255)
References: Proc Natl Acad Sci U S A. 2018 May 15;115(20):5283-5288. (PMID: 29717038)
FASEB J. 2020 Sep;34(9):12963-12975. (PMID: 32772418)
Cell. 2017 Feb 9;168(4):707-723. (PMID: 28187290)
Nature. 2014 Jun 5;510(7503):92-101. (PMID: 24899309)
Int J Mol Sci. 2019 May 30;20(11):. (PMID: 31151303)
J Clin Invest. 2019 Jun 17;129(7):2964-2979. (PMID: 31205032)
Shock. 2020 Jun;53(6):761-771. (PMID: 31318834)
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3818-21. (PMID: 23684894)
Nat Rev Drug Discov. 2009 Oct;8(10):794-805. (PMID: 19794443)
Immunol Rev. 2008 Aug;224:141-65. (PMID: 18759925)
Am J Pathol. 2020 Sep;190(9):1782-1788. (PMID: 32650004)
Nature. 2019 May;569(7756):428-432. (PMID: 31043740)
Food Chem Toxicol. 2021 Oct;156:112516. (PMID: 34411643)
J Neurooncol. 2016 Aug;129(1):39-45. (PMID: 27174198)
Oncogene. 2023 Feb;42(9):693-707. (PMID: 36596844)
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12499-504. (PMID: 16888035)
Proc Natl Acad Sci U S A. 2020 Sep 1;117(35):21576-21587. (PMID: 32801214)
Cancer Lett. 2016 Feb 28;371(2):187-93. (PMID: 26683769)
Stroke. 2015 Jul;46(7):1916-22. (PMID: 25991416)
Neurocrit Care. 2022 Jun;36(3):905-915. (PMID: 34873674)
Front Immunol. 2020 May 07;11:784. (PMID: 32457745)
Nature. 1956 Dec 22;178(4547):1391-2. (PMID: 13387716)
Eur J Surg. 1995 Feb;161(2):115-22. (PMID: 7539633)
BMJ. 2003 Jul 19;327(7407):117-8. (PMID: 12869428)
Redox Biol. 2020 Jan;29:101405. (PMID: 31926628)
J Biol Chem. 2010 Oct 22;285(43):32720-32733. (PMID: 20732876)
FASEB J. 2020 Jul;34(7):9074-9086. (PMID: 32400048)
Am J Respir Crit Care Med. 2014 Oct 15;190(8):886-97. (PMID: 25162465)
FASEB J. 2019 Jan;33(1):114-125. (PMID: 29957058)
Cancer Immunol Res. 2020 Oct;8(10):1230-1235. (PMID: 33004412)
Pharmacol Ther. 2023 Aug;248:108454. (PMID: 37268114)
Pediatr Res. 2012 Feb;71(2):168-78. (PMID: 22258128)
Asian J Androl. 2021 Jan-Feb;23(1):109-115. (PMID: 32687069)
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):5827-5828. (PMID: 29769328)
Nutrients. 2020 Jul 26;12(8):. (PMID: 32722632)
Clin Cancer Res. 2015 Mar 15;21(6):1248-57. (PMID: 25589616)
Mol Carcinog. 2013 Sep;52(9):726-38. (PMID: 22517541)
Front Physiol. 2021 Apr 01;12:663869. (PMID: 33868029)
Int J Mol Sci. 2021 Jul 17;22(14):. (PMID: 34299273)
Anticancer Res. 2016 Jan;36(1):27-37. (PMID: 26722025)
Annu Rev Immunol. 2022 Apr 26;40:45-74. (PMID: 35471840)
Proc Natl Acad Sci U S A. 2013 Apr 16;110(16):6530-5. (PMID: 23553837)
Cardiovasc Toxicol. 2018 Jun;18(3):268-283. (PMID: 29196978)
J Nutrigenet Nutrigenomics. 2008;1(4):172-7. (PMID: 19776625)
Chest. 2017 Mar;151(3):555-563. (PMID: 27884766)
Bioorg Med Chem Lett. 2013 Jul 1;23(13):3732-7. (PMID: 23726028)
EClinicalMedicine. 2021 Jul 08;38:100997. (PMID: 34505026)
Front Pharmacol. 2020 Sep 25;11:598858. (PMID: 33071800)
J Clin Invest. 2012 Jan;122(1):178-91. (PMID: 22182838)
Dig Dis Sci. 2012 Oct;57(10):2580-91. (PMID: 22588244)
Cancer Discov. 2021 Oct;11(10):2602-2619. (PMID: 34031121)
Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):E3240-9. (PMID: 27226306)
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):136-141. (PMID: 27980032)
BMC Cancer. 2014 Nov 18;14:841. (PMID: 25406731)
J Mol Cell Cardiol. 2016 Sep;98:128-37. (PMID: 27496380)
PLoS One. 2013 Sep 13;8(9):e75107. (PMID: 24058654)
Cancer Metastasis Rev. 2018 Sep;37(2-3):545-555. (PMID: 29971573)
JAMA Netw Open. 2019 May 3;2(5):e192535. (PMID: 31050774)
J Lipid Res. 2014 Jun;55(6):1150-64. (PMID: 24634501)
Neurochem Int. 2021 Nov;150:105197. (PMID: 34592333)
Science. 1999 Aug 20;285(5431):1276-9. (PMID: 10455056)
Mol Med Rep. 2021 Sep;24(3):. (PMID: 34278494)
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. (PMID: 30647111)
Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2314085121. (PMID: 38330013)
Mol Cancer Ther. 2018 Feb;17(2):474-483. (PMID: 29284644)
Cancer Res. 2020 Dec 15;80(24):5597-5605. (PMID: 33023946)
Molecules. 2020 Nov 24;25(23):. (PMID: 33255197)
Int J Mol Sci. 2021 Jul 01;22(13):. (PMID: 34281173)
Pharmacol Ther. 2021 Feb;218:107670. (PMID: 32891711)
Br J Cancer. 2020 Apr;122(8):1260-1270. (PMID: 32114592)
Br J Pharmacol. 2023 Jun;180(12):1597-1615. (PMID: 36508312)
J Med Chem. 2021 Feb 25;64(4):1856-1872. (PMID: 33550801)
Cancer Epidemiol Biomarkers Prev. 1992 Jul-Aug;1(5):395-403. (PMID: 1339049)
Cancer Discov. 2021 Oct;11(10):2372-2374. (PMID: 34598950)
Eur J Pharm Sci. 2013 Mar 12;48(4-5):619-27. (PMID: 23291046)
Sci Transl Med. 2018 Apr 11;10(436):. (PMID: 29643230)
J Med Chem. 2021 Jan 14;64(1):184-215. (PMID: 33369424)
Nat Commun. 2017 Dec 22;8(1):2256. (PMID: 29273790)
Pharmacol Ther. 2005 Jan;105(1):7-21. (PMID: 15626453)
Biochim Biophys Acta Gen Subj. 2023 Sep;1867(9):130394. (PMID: 37315719)
Proc Natl Acad Sci U S A. 2021 Oct 12;118(41):. (PMID: 34607951)
J Exp Clin Cancer Res. 2016 Apr 02;35:61. (PMID: 27039073)
Clin Nutr. 2022 Feb;41(2):433-440. (PMID: 35007812)
Immunity. 2019 Jul 16;51(1):27-41. (PMID: 31315034)
J Pharmacol Exp Ther. 2016 Jun;357(3):529-36. (PMID: 26989141)
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9772-7. (PMID: 15994227)
Toxicol Appl Pharmacol. 2015 Jul 15;286(2):102-11. (PMID: 25827057)
Adv Exp Med Biol. 2020;1274:71-99. (PMID: 32894508)
J Exp Med. 2018 Jan 2;215(1):115-140. (PMID: 29191914)
Am J Pathol. 2011 Feb;178(2):525-36. (PMID: 21281786)
Anticancer Res. 2013 Dec;33(12):5261-5271. (PMID: 24324059)
J Mol Histol. 2006 May;37(3-4):133-41. (PMID: 16957870)
Front Immunol. 2023 Jan 26;14:1122430. (PMID: 36776862)
Mol Metab. 2022 Feb;56:101426. (PMID: 34971802)
Front Pharmacol. 2019 Jun 25;10:731. (PMID: 31293429)
Am J Physiol Heart Circ Physiol. 2022 Oct 1;323(4):H670-H687. (PMID: 35985007)
PLoS One. 2014 Apr 23;9(4):e96221. (PMID: 24760204)
Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):e20-30. (PMID: 12588785)
Am J Transl Res. 2010 Jul 22;2(4):447-57. (PMID: 20733953)
Nat Rev Cancer. 2019 Mar;19(3):133-150. (PMID: 30755690)
Arch Pharm (Weinheim). 2022 Mar;355(3):e2100367. (PMID: 34802171)
Nature. 2004 Feb 5;427(6974):504. (PMID: 14765186)
Arch Surg. 1997 Nov;132(11):1222-9; discussion 1229-30. (PMID: 9366716)
Anticancer Res. 2019 Jul;39(7):3651-3660. (PMID: 31262891)
Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373)
Nutrients. 2020 Oct 28;12(11):. (PMID: 33126566)
Am J Respir Cell Mol Biol. 2015 Jan;52(1):46-55. (PMID: 24922186)
Science. 1959 Oct 9;130(3380):918-9. (PMID: 13823184)
معلومات مُعتمدة: P42 ES004699 United States ES NIEHS NIH HHS; R35 ES030443 United States ES NIEHS NIH HHS
فهرسة مساهمة: Keywords: eicosanoid; immunonutrition; inflammation resolution; omega-3 fatty acids; soluble epoxide hydrolase
المشرفين على المادة: EC 3.3.2.- (Epoxide Hydrolases)
0 (Fatty Acids)
تواريخ الأحداث: Date Created: 20240208 Date Completed: 20240214 Latest Revision: 20240219
رمز التحديث: 20240219
مُعرف محوري في PubMed: PMC10873624
DOI: 10.1073/pnas.2314085121
PMID: 38330013
قاعدة البيانات: MEDLINE
الوصف
تدمد:1091-6490
DOI:10.1073/pnas.2314085121